Please enable Javascript
Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, Professor of Medicine and Urology at the Yale School of Medicine
Articles by Daniel P. Petrylak, MD
Panel Comments on Most Impactful Studies and Data in Bladder Cancer
Vadim Koshkin, MD
Roundtable
|
July 7, 2023
The panel discusses studies and areas of interest related to treatment options for advanced bladder cancer.
View More
How Do Prior Therapies in the Perioperative Space Inform Subsequent Treatment Selection?
Vadim Koshkin, MD
Roundtable
|
July 7, 2023
The panel discussed how treatments used in the metastatic space are moving into the perioperative setting.
View More
Can Targeted Therapies Move the Field Toward More Individualized Bladder Cancer Treatment?
Vadim Koshkin, MD
Roundtable
|
July 7, 2023
The panel discusses the potential for more targeted treatments making their way into the advanced bladder cancer space.
View More
Treatment Sequencing and Use of Biomarkers to Guide Treatment Selection in Bladder Cancer
Vadim Koshkin, MD
Roundtable
|
July 7, 2023
The panel addresses treatment sequencing decisions following disease relapse.
View More
What Are the Treatment Options for Patients With Platinum-Ineligible Bladder Cancer?
Vadim Koshkin, MD
Roundtable
|
August 22, 2023
The panel discusses the approach to treating patients with platinum-ineligible bladder cancer.
View More
Panel Comments on Ongoing EV-302 Trial, Patient Management Considerations in Bladder Cancer
Vadim Koshkin, MD
Urothelial Carcinoma
|
July 7, 2023
The panel discusses patient characteristics and treatment sequencing considerations.
View More
Treatment Considerations for Patients With Cisplatin-Ineligible Bladder Cancer
Vadim Koshkin, MD
Roundtable
|
July 7, 2023
The panel discusses the approach to treating patients with cisplatin-ineligible bladder cancer.
View More
Panelists Discuss Treatment Approach for Patients With Cisplatin-Eligible Bladder Cancer
Vadim Koshkin, MD
Roundtable
|
July 7, 2023
The panel discusses the approach to treating patients with cisplatin-eligible bladder cancer.
View More
TROPHY-U-01: Sacituzumab Govitecan for Platinum-ineligible Metastatic UC
Daniel P. Petrylak, MD
ASCO GU Symposium 2023
|
April 3, 2023
Daniel P. Petrylak, MD, overviews the TROPHY-U-01 study for platinum-ineligible patients with metastatic UC.
View More